Antitumor effect of everolimus in a patient with type 3 gastric neuroendocrine tumor.

Abstract

BACKGROUND:

Gastric neuroendocrine tumors (NET) are rare and are classified into 3 types: type 1 and 2 (characterized by hypergastrinemia), and type 3 (characterized by normal gastrin). Surgery is the standard procedure, and systemic treatment is reserved for unresectable disease. Currently, targeted therapies are being evaluated in NET. The activity of everolimus, an mTOR inhibitor, has been shown in pancreatic NET but not reported in type 3 gastric carcinoid tumors.

CASE REPORT:

Here we report a case of a patient who, after multiple lines of systemic therapy, had a prolonged disease control of nearly 1 year, significant clinical benefit, and minor tumor shrinkage with oral everolimus 10 mg continuously.

CONCLUSION:

There is no effective treatment for type 3 gastric carcinoid tumors. The frequency of mTOR expression in these tumors is not known, but the case reported here suggests that inhibition of this pathway may play an important role.

• Authors: Giovanni M Bariani, José B Carvalheira, Rachel P Riechelmann
• Journal: Onkologie (Onkologie) Vol. 36 Issue 9 Pg. 502-4 ( 2013) ISSN: 1423-0240 [Electronic] Switzerland
• PMID: 24051927 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2013 S. Karger GmbH, Freiburg.

Chemical References

• Antineoplastic Agents
• Everolimus
• Sirolimus

Topics

• Antineoplastic Agents (therapeutic use)
• Everolimus
• Humans
• Male
• Middle Aged
• Neuroendocrine Tumors (diagnostic imaging, drug therapy)
• Sirolimus (analogs & derivatives, therapeutic use)
• Stomach Neoplasms (diagnostic imaging, drug therapy)
• Tomography, X-Ray Computed
• Treatment Outcome